Ferring International Center S.A. - Product Pipeline Review

Global Markets Direct’s, ‘Ferring International Center S.A. - Product Pipeline Review - 2016’, provides an overview of the Ferring International Center S.A.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ferring International Center S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Ferring International Center S.A.

The report provides overview of Ferring International Center S.A. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Ferring International Center S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Ferring International Center S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Ferring International Center S.A.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ferring International Center S.A.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ferring International Center S.A.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ferring International Center S.A. Snapshot 6

Ferring International Center S.A. ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ferring International Center S.A. Snapshot 6

Ferring International Center S.A. Overview 6

Key Information 6

Key Facts 6

Ferring International Center S.A. - Research and Development Overview 7

Key Therapeutic Areas 7

Ferring International Center S.A. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Ferring International Center S.A. - Pipeline Products Glance 15

Ferring International Center S.A. - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

Ferring International Center S.A. - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Ferring International Center S.A. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Ferring International Center S.A. - Drug Profiles 19

follitropin delta 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Testavan 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

degarelix acetate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

elobixibat 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

selepressin 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

barusiban 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

carbetocin 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

FE-999301 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

merotocin 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

FE-201874 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

FE-204038 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

FE-999310 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule for Undisclosed Indication 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Ferring International Center S.A. - Pipeline Analysis 34

Ferring International Center S.A. - Pipeline Products by Target 34

Ferring International Center S.A. - Pipeline Products by Route of Administration 35

Ferring International Center S.A. - Pipeline Products by Molecule Type 36

Ferring International Center S.A. - Pipeline Products by Mechanism of Action 37

Ferring International Center S.A. - Recent Pipeline Updates 38

Ferring International Center S.A. - Dormant Projects 41

Ferring International Center S.A. - Discontinued Pipeline Products 42

Discontinued Pipeline Product Profiles 42

DR-2011 42

Ferring International Center S.A. - Locations and Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Ferring International Center S.A., Key Information 6

Ferring International Center S.A., Key Facts 6

Ferring International Center S.A. - Pipeline by Indication, ...

List of Tables

Ferring International Center S.A., Key Information 6

Ferring International Center S.A., Key Facts 6

Ferring International Center S.A. - Pipeline by Indication, 2016 8

Ferring International Center S.A. - Pipeline by Stage of Development, 2016 9

Ferring International Center S.A. - Monotherapy Products in Pipeline, 2016 10

Ferring International Center S.A. - Partnered Products in Pipeline, 2016 11

Ferring International Center S.A. - Partnered Products/ Combination Treatment Modalities, 2016 12

Ferring International Center S.A. - Out-Licensed Products in Pipeline, 2016 13

Ferring International Center S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 14

Ferring International Center S.A. - Pre-Registration, 2016 15

Ferring International Center S.A. - Phase III, 2016 16

Ferring International Center S.A. - Phase II, 2016 17

Ferring International Center S.A. - Preclinical, 2016 18

Ferring International Center S.A. - Pipeline by Target, 2016 34

Ferring International Center S.A. - Pipeline by Route of Administration, 2016 35

Ferring International Center S.A. - Pipeline by Molecule Type, 2016 36

Ferring International Center S.A. - Pipeline Products by Mechanism of Action, 2016 37

Ferring International Center S.A. - Recent Pipeline Updates, 2016 38

Ferring International Center S.A. - Dormant Developmental Projects,2016 41

Ferring International Center S.A. - Discontinued Pipeline Products, 2016 42

Ferring International Center S.A., Other Locations 43

Ferring International Center S.A., Subsidiaries 44

List of Figures

List of Figures

Ferring International Center S.A. - Pipeline by Top 10 Indication, 2016 8

Ferring International Center S.A. - Pipeline by Stage of Development, ...

List of Figures

Ferring International Center S.A. - Pipeline by Top 10 Indication, 2016 8

Ferring International Center S.A. - Pipeline by Stage of Development, 2016 9

Ferring International Center S.A. - Monotherapy Products in Pipeline, 2016 10

Ferring International Center S.A. - Out-Licensed Products in Pipeline, 2016 13

Ferring International Center S.A. - Pipeline by Target, 2016 34

Ferring International Center S.A. - Pipeline by Route of Administration, 2016 35

Ferring International Center S.A. - Pipeline by Molecule Type, 2016 36

Ferring International Center S.A. - Pipeline Products by Mechanism of Action, 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports